SC144 is an orally bioavailable gp130 inhibitor.1 It inhibits phosphorylation of STAT1, STAT3, and Akt induced by leukemia inhibitory factor (LIF) and IL-6, but not IFN-γ, in OVCAR-8 ovarian cancer cells when used at a concentration of 20 ?M. SC144 induces cell cycle arrest at the G0/G1 phase in MDA-MB-435 breast and HT-29 colorectal cancer cells and inhibits proliferation of 14 cancer cell lines, including prostate, ovarian, lung, breast, and colorectal cancer cells, with IC50 values ranging from 0.4 to 4 ?M.2 It reduces tumor growth in OVCAR-8 and MDA-MB-435 mouse xenograft models.1,2
1.Xu, S., Grande, F., Garofalo, A., et al.Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancerMol. Cancer Ther.12(6)937-949(2013) 2.Plasencia, C., Grande, F., Oshima, T., et al.Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activityCancer Biol. Ther.8(5)458-465(2009)